Coeptis Therapeutics Holdings (Nasdaq: COEP) and Z Squared Inc. announced a definitive merger agreement on April 25, 2025, to create the world’s largest publicly traded dogecoin-focused mining company. As part of the transaction, Coeptis will spin off its biopharmaceutical operations.

Coeptis Therapeutics Holdings（NASDAQ：COEP）和Z Squared Inc.於2025年4月25日宣布了一項確定的合併協議，以創建全球最大的以Dogecoin為中心的最大公開交易的礦業公司。作為交易的一部分，Coeptis將脫離其生物藥物操作。

Upon completion of the merger, Z Squared will become a wholly owned subsidiary of Coeptis. In exchange for 9,000 U.S.-based dogecoin (DOGE) mining machines, shareholders of Z Squared will receive equity in Coeptis.

合併完成後，Z平方將成為Coeptis的全資子公司。為了換取9,000個總部位於美國的Dogecoin（Doge）採礦機，Z Squared的股東將獲得Coeptis的股權。

The transaction, approved by both boards of directors, is subject to regulatory clearances, Nasdaq listing compliance, and shareholder approval. Closure is anticipated in Q3 2025, with the combined entity rebranding as Z Squared, Inc. and trading on Nasdaq.

兩家董事會批准的交易均受監管許可，納斯達克上市合規性和股東批准的約束。預計第3季度的第3季度將關閉，合併後的實體將Z Squared，Inc。和在納斯達克交易的交易。

Z Squared executives David Halabu and Michelle Burke will helm the merged company as CEO and COO, respectively. Coeptis CEO Dave Mehalick will step down from the board post-closure. Halabu, founder of Group 10 Capital Management, highlighted the merger's aim to provide investors with concentrated exposure to dogecoin's $27 billion market cap.

Z Squared高管David Halabu和Michelle Burke將分別擔任合併後的公司擔任首席執行官和COO。 Coeptis首席執行官戴夫·梅哈里克（Dave Mehalick）將在關閉後的董事會中辭職。第10組資本管理的創始人Halabu強調了合併的目的，目的是為投資者提供集中在Dogecoin的270億美元市場上限上。

The new company will dedicate its efforts to mining dogecoin and collecting proof-of-work blockchain rewards. Mehalick elaborated that shareholders will have the opportunity to participate in dogecoin markets while retaining an interest in the spun-off biopharma operations, which will continue independently.

這家新公司將致力於開採Dogecoin並收集工作證明區塊鏈獎勵。 Mehalick闡述了股東將有機會參與Dogecoin市場，同時保留對旋轉生物製藥業務的興趣，這將繼續獨立。

Coeptis' biopharmaceutical divisions, developing cell therapies for cancer and infectious diseases, will continue operating within the spun-off entity. Its technology division, featuring AI and automation tools, will remain with the merged company.

Coeptis的生物藥物分裂，開發針對癌症和傳染病的細胞療法，將繼續在旋轉實體中運作。它的技術部門具有AI和自動化工具，將保留在合併的公司中。

Z Squared, specializing in the mining of DOGE and litecoin (LTC), aims to capitalize on the burgeoning altcoin mining sector. Further transaction details, including leadership economic interests and merger agreement terms, will be filed with the U.S. Securities and Exchange Commission (SEC).

Z Squared專門研究Doge和Litecoin（LTC）的開採，旨在利用新興的Altcoin礦業領域。進一步的交易詳細信息，包括領導經濟利益和合併協議條款，將提交美國證券交易委員會（SEC）。

Investors are directed to relevant filings with the SEC for complete information on leadership economic interests and merger terms.

投資者被指向與SEC的相關文件，以獲取有關領導經濟利益和合併條款的完整信息。